By contrast, recent data from clinical trials of anti-CD19 or anti-CD22 CAR T cells in ALL have demonstrated that corticosteroids may mitigate the CAR T cell–related toxicities without influence on the efficacy (127). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.